Albany, NY -- (SBWIRE) -- 05/04/2018 -- Osteomalacia Drugs Market:Overview
Bone is a dynamic tissue that constantly undergoes remodeling. Remodeling is a five-step process that consists of resting, activation, resorption, reversal, and formation. This process utilizes osteoclasts (old bones reabsorbed) and osteoblasts (new bones formed). If there is imbalance between the re-absorption and formation, it can lead to bone loss and diseases such as osteoporosis and osteomalacia. Osteomalacia differs from osteoporosis wherein bone thinning is caused. Osteomalacia is marked by softening of bones and it is caused by severe deficiency of vitamin D. The deficiency of vitamin D affects the bone-maturing process among children and young adults. It may lead to bowing of bones, especially weight-bearing bones of the legs. If the vitamin-D deficiency occurs in children, it leads to rickets. In adults, it leads to osteomalacia. Typically, the human body utilizes minerals including phosphates to build bones. Individuals might suffer from osteomalacia if they do not get minerals in sufficient amounts from their diet or if minerals are not absorbed properly. Apart from this, certain surgeries (stomach surgery), autoimmune disorders, kidney and/or liver disorders, or drugs (phenytoin, phenobarbital) can also cause osteomalacia.
Download PDF Brochure of Report:
https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=42143
Diagnosis of osteomalacia is performed by using X-ray or other diagnostic tests such as alkaline phosphatase test and parathyroid hormone test. Pain caused by osteomalacia is linked with the lower back, the pelvis, the hips, the legs, and the ribs. Pain intensifies during nights or when the patient puts pressure on the legs. Osteomalacia can occur in individuals with vitamin-D metabolism disorder, kidney failure, mineral deficiency, cancer, or liver diseases. According to Vitamin D Council, approximately one billion individuals (i.e. 15% of the global population) were suffering from vitamin-D deficiency in 2016. Osteomalacia is caused by deficiencies or insufficiencies of vitamin D-25-hydroxylase, gastrointestinal and hepatic diseases, hyperparathyroidism, pseudo-hypoparathyroidism, and chronic renal insufficiency. Rising number of people suffering from rickets and osteomalacia across the globe due to high prevalence of these diseases is considered an important driver for the market. In addition, availability of new drugs such as parathyroid hormone (PTH) and burosumab to treat pediatric and adult patients with hypophosphatemia is driving the osteomalacia drugs market. In 2015, Asfotase Alfa was granted the breakthrough therapy designation by the U.S. FDA. The regulatory approval of the drug would propel the global osteomalacia drugs market in the near future.
Request to View TOC of Report –
https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=42143
The global osteomalacia drugs market can be segmented based on disease type, therapy type, distribution channel, and geography. Based on disease type, the market can be segmented into vitamin-D-related osteomalacia, hypocalcemia-related osteomalacia, hypophosphatemia-related osteomalacia, and others. Based on therapy type, the market can be segmented into diet-based, vitamin D, phosphate, calcium, and others. Based on distribution channel, the market can be segmented into hospital pharmacies, retail pharmacies, and others.
Geographically, the global osteomalacia drugs market can be segmented into five regions viz. North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is expected to dominate the global osteomalacia drugs market during the forecast period, due to well-developed health care infrastructure, high requirement for vitamin D, changing lifestyle, and increasing health care expenditure in the region. Nearly 40% of the U.S. population is suffering from vitamin-D deficiency. Hence, the country witnesses high prevalence of bone-related disorders. Additionally, increasing awareness among people regarding different types of bone disorders and availability of well-developed technologies contribute toward growth of the market. Europe is expected to be the second-largest market for osteomalacia drugs from 2017 to 2025, due to increased funding for research and development by governments in the region. The osteomalacia drugs market in Asia Pacific is expected to witness rapid growth, due to constantly developing health care infrastructure in key economies and presence of a large pool of patients in the region. Other regions such as Latin America and Middle East & Africa are expected to hold least share of the global osteomalacia drugs market between 2017 and 2025.
Key players operating in the global osteomalacia drugs market are Kyowa Hakko Kirin International plc, Alexion Pharmaceuticals, Zeria Pharmaceutical, Co., Ltd., Pfizer, Inc., Sun Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Mankind Pharma, Chemvon Biotechnology (Shanghai) Co. Ltd., Pharmavite LLC, and Abbott Laboratories.
Request to View Discount –
https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=42143